Yokohama, Japan

Toshihiko Aiba

This inventor holds 1 USPTO granted patent. Top assignees: Keio University, Regimmune Corporation. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Toshihiko Aiba. Retrieved from https://idiyas.com/inventor/toshihiko-aiba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Toshihiko Aiba

Introduction

Toshihiko Aiba is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the activation of natural killer T cells. His work has implications for various therapeutic applications.

Latest Patents

Toshihiko Aiba holds a patent for a compound or salt thereof that acts as a natural killer T cell activator. The patent addresses the need for a novel compound capable of activating these cells, which play a crucial role in the immune response. The compound is represented by a specific formula, and it is designed to enhance the effectiveness of natural killer T cell activating agents and pharmaceutical compositions.

Career Highlights

Throughout his career, Aiba has been associated with prestigious institutions such as Keio University and Regimmune Corporation. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Toshihiko Aiba has collaborated with notable colleagues, including Yukari Fujimoto and Emi Kashiwabara. These partnerships have fostered innovation and have been instrumental in the development of his research.

Conclusion

Toshihiko Aiba's contributions to the field of natural killer T cell activation highlight his innovative spirit and dedication to advancing medical science. His patent and collaborations reflect his commitment to improving therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…